The FDA has issued new information about this safety issue, see the FDA Drug Safety Communication issued 5-7-2012. Safety AnnouncementAdditional Information for PatientsAdditional Information for Healthcare […]

Este informe actualizado se hace en seguimiento al Comunicado de la FDA sobre la seguridad de los medicamentos: Estudio de seguridad en curso de Revlimid (lenalidomida) […]

The FDA has issued new information about this safety issue, see the FDA Drug Safety Communication issued 05-14-2012. Safety AnnouncementAdditional Information for PatientsAdditional Information for Healthcare […]

[11-20-2018] The Food and Drug Administration (FDA) is warning that when the multiple sclerosis (MS) medicine Gilenya (fingolimod) is stopped, the disease can become much worse […]

The FDA has issued new information about this safety issue, see the FDA Drug Safety Communication issued 6-29-2012 Safety AnnouncementAdditional Information for PatientsAdditional Information for Healthcare […]

Esta actualización se hace a manera de seguimiento al Comunicado sobre la seguridad de los medicamentos de la FDA: Nueva información sobre la prolongación del intervalo […]

Safety AnnouncementTable 1.  List of ondansetron products to be voluntarily withdrawn from the U.S. marketReference  Safety Announcement [12-4-2012] The U.S. Food and Drug Administration (FDA) is […]

[04-15-2011] To further evaluate the safety of Long-Acting Beta-Agonists (LABAs) when used in combination with inhaled corticosteroids for the treatment of asthma, the U.S. Food and […]

Anuncio de seguridadInformación adicional para consumidoresInformación adicional para profesionales de la saludResumen de datosFuentes Anuncio de seguridad 13 de septiembre del 2012. La Administración de Alimentos […]